// App-Quantinova.ai

: IPH6501 Is a Novel NKp46-Targeting Tetraspecific Antibody-Based Natural Killer Cell Engager Therapeutic (ANKET) Armed with a Non-Alpha IL-2 Variant and Developed for the Treatment of CD20-Positive Malignancies

Researchers

Presenter

  • Olivier Demaria

Principal Investigators

  • Guillaume Habif

  • François Le Floch

  • Laura Chiossone

  • Romain Remark

  • Marie Vetizou

  • Nadia Maurel

  • Laurent Gauthier

  • Yannis Morel

  • Carine Paturel

  • Eric Vivier

  • Pascale Andre

Medical Centers

  • Centre d'Immunologie de Marseille-Luminy (CIML), Marseille, France

Locations

  • France

Companies

  • N/A

Study Components

Therapeutic Area

  • Blood/haematological Diseases

  • Oncology (ONC)

Disease

  • B-Cell Non-Hodgkin Lymphoma

  • B cell lymphomas

  • Non‐Hodgkin Lymphoma

  • Lymphomas

Biomarkers

  • Natural Killer cells

  • Cluster of Differentiation 25

  • IL-2 receptor β

  • Interleukin-2

  • Regulatory T cells

Drug/Treatment

  • Obinutuzumab

  • Obinutuzumab Intravenous

  • Interleukin

  • ofatumumab Intravenous

  • Rituximab

Outcome

  • N/A

Study Design

  • Efficacy

  • Superiority

Phase

  • NA

Study Id's

  • N/A

Sponsors

  • N/A

Result

  • N/A

Copyright © 2026. QuantiNova All rights reserved